8-K: Current report
Published on November 16, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
(
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On November 16, 2026, iBio, Inc. (the “Company”) issued a press release highlighting extended preclinical data from a non-human primate (NHP) study of IBIO-610 presented at ObesityWeek 2026, as well as preclinical data from its amylin program to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.
The new data for the Company’s long-acting Activin E-targeting antibody, IBIO-610, builds on previously reported findings from an obese NHP study, extending observations through 28 weeks. The study included obese NHPs receiving IBIO-610 (n=5) or vehicle (n=6). IBIO-610 was initially administered every eight weeks, followed by more frequent dosing and a dose-free period.
Key findings were as follows:
·At week 28, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle, with change in body weight first observed around week 18. At week 24, total fat was 9.6% lower, abdominal subcutaneous fat was 16.6% lower and visceral fat was 10.96% lower relative to vehicle, while lean mass was generally maintained.
·Near-complete suppression of active Activin E was observed through week 28.
The Company’s amylin program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3.
Key findings were as follows:
·In vitro, the Company’s antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.
·In a single-dose study in lean rats, the rats dosed with the Company’s selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.
The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.
Item 8.01. Other Events.
On November 16, 2026, the Company issued a press release highlighting extended preclinical data from a non-human primate (NHP) study of IBIO-610 presented at ObesityWeek 2026, as well as preclinical data from its amylin program to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.
The new data for the Company’s long-acting Activin E-targeting antibody, IBIO-610, builds on previously reported findings from an obese NHP study, extending observations through 28 weeks. The study included obese NHPs receiving IBIO-610 (n=5) or vehicle (n=6). IBIO-610 was initially administered every eight weeks, followed by more frequent dosing and a dose-free period.
Key findings were as follows:
·At week 28, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle, with change in body weight first observed around week 18. At week 24, total fat was 9.6% lower, abdominal subcutaneous fat was 16.6% lower and visceral fat was 10.96% lower relative to vehicle, while lean mass was generally maintained.
·Near-complete suppression of active Activin E was observed through week 28.
The Company’s amylin program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3.
Key findings were as follows:
·In vitro, the Company’s antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.
·In a single-dose study in lean rats, the rats dosed with the Company’s selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | | Description |
99.1 | ||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |